T1 Energy Inc. (NYSE: TE) — A Revocable Tax Credit Wearing a Solar Factory, Now Under Whistleblower and Grand-Jury Fire

Independent equity research · Report date: 2026-07-03

The main body of this article takes no position and sets no price target; it analyzes T1 Energy only through embedded expectations and scenarios. The single exception is the clearly-labeled Claude’s Take block below — the author’s own subjective view.

⚡ Claude’s Take

This block is the author’s own independent, subjective opinion. It is general information, not investment advice. Everything from the Executive Summary onward is position-free and carries no price target.

Verdict: AVOID here (~$8.50–9.50). Speculation-only, and even then not a clean short. T1 Energy is not an investable business in any conventional sense — it is a binary policy option wrapped around a sub-scale, no-moat, cash-burning solar-module assembler with negative tangible equity, a share count that tripled in eighteen months (with authorized shares just doubled again to 1 billion), a business whose gross profit is entirely a tax credit (ex-45X, FY25 gross profit would be a ~$(105)M loss), and revenue that in Q1 2026 was ~100% sales to a single related party — Trina, the Chinese company it bought the plant from, which is now dumping its own stock. On top of that sits the crux: a three-firm short campaign (Culper, then two Fuzzy Panda reports) alleging that the tax credits which are the company’s entire reason for existing are being fraudulently claimed on Chinese-sourced cells. That thesis is not idle: it is corroborated in outline by T1’s own filings (eligibility rests on supplier self-certifications and T1’s own conclusion that a Singapore entity, Evervolt, which bought Trina’s IP, is “not a foreign entity of concern”), and it sits alongside a DOJ grand-jury subpoena and an SEC document request over a director’s 2H-2023 stock sales, a Chief Accounting Officer fired two weeks after the first short report, terminated-and-litigated customer offtake (RWE), and no formal company rebuttal to the invoice allegations. When the entire equity value is “we qualify for the subsidy,” and three short sellers plus a whistleblower plus the DOJ are all circling the question “do you actually qualify,” you do not need to resolve the accounting to know the risk-adjusted answer is stay out.

I stop short of “short it” for two honest reasons. First, there is genuine right-tail optionality: the Section 232 polysilicon decision is expected within days (~July 4, 2026), and because T1 buys American polysilicon (Hemlock), a tariff wall is a real “heads-I-win” catalyst that could squeeze a heavily-shorted ~$2.5B float violently — the stock already doubled last quarter (m3 ≈ +100% raw). Second, on a clean read (if FEOC holds and G1+G2 reach a mid-cycle ~$150–250M EBITDA run-rate), you could sketch a $4–7 “business” value — below today’s price, but not zero. The distribution is brutally bimodal: near-zero in a restatement/going-concern tail, low-double-digits in a §232-win-plus-FEOC-holds tail. That is a coin-flip with a federal investigation on one side — the definition of un-underwritable for a fundamental fund. Framing: event-driven falling-knife-that-bounced, not value, not quality. Conviction: medium. Flips bullish if T1 publishes a credible, audited FEOC/MACR compliance rebuttal (independent supplier-of-record documentation) and §232 lands with hard per-watt tariffs. Flips outright-bearish (toward zero) if the auditor forces a 45X restatement or the DOJ/SEC matter escalates to charges. Tag: “The moat is a tax credit, and the whistleblower has the invoices.”

📈 Stock Price Action — Five-Year Event Map

T1 (as FREYR Battery until February 2025) has round-tripped almost to zero and back. From a ~$16.94 intraday peak in October 2022 (post-IRA battery-SPAC euphoria) it collapsed ~95% to a $0.91 low in September 2024 as the legacy battery business imploded; the December 2024 pivot to buy Trina’s US solar plant, plus the 2025 solar ramp, drove a ~10x rebound to a $12.49 52-week high (January 2026). As of the 2026-07-02 close of ~$8.56 (recent trades ~$9), it sits roughly ~30–45% below its January high and ~9x above its 2024 low, in a violently volatile ($1.15–$12.49 52-week range) speculative tape. Price levels are Fact; attributed drivers are Interpretation.

Cycle narrative. (1–3) The FREYR chapter was a textbook clean-energy SPAC boom-bust: a pre-revenue Norwegian battery developer hyped into the 2022 IRA wave, then ground to ~$0.91 as Giga Arctic slipped and cash ran out. (4) The equity was resurrected by a different business — buying Trina Solar’s US module plant (G1_Dallas) in December 2024 and rebranding to T1; the 2025 ramp to 5GW nameplate and the promise of 45X subsidy dollars produced a ~13x move off the low. (5) 2026 opened with the hangover: FEOC sourcing rules took effect January 1, Culper Research’s January 21 short report alleged the whole structure is China-tethered, the CAO was terminated February 5, and relentless dilution capped the stock. (6) April’s convertible raise and a genuinely improved Q1’26 print (17% gross margin, “record” $9.1M adjusted EBITDA) sparked a doubling. (7) Fuzzy Panda’s June 10 whistleblower-invoice report — alleging that same $9.1M is really negative $32.3M once improperly-claimed 45X credits are stripped — knocked the stock ~9%, only partly offset by a Bernstein Market-Perform initiation ($9 target). Every leg of this chart is narrative- and policy-driven; none of it rests on durable earnings.

1. Executive Summary

T1 Energy Inc. is the former FREYR Battery — a failed lithium-battery SPAC that, in December 2024, bought Trina Solar’s US module-manufacturing operation (the 5GW “G1_Dallas” plant in Wilmer, Texas), rebranded to T1 in February 2025, and is now attempting to become a vertically-integrated American solar manufacturer. It is building “G2_Austin,” a 2.1GW solar-cell fab (first output targeted Q4 2026, ~$425M total capex, ~$225M still unfunded). FY2025 was its first real revenue year: $755.3M of module sales at a 7.4% gross margin, a −$179.7M operating loss and a −$367.8M net loss (EPS −$2.19). Two facts define the quality of that revenue: 77.7% of FY25 sales (and ~100% of Q1’26 sales) went to a single related party — Trina (the very Chinese company T1 bought the plant from), under an offtake baked into the acquisition’s purchase accounting; and the entire gross profit is a subsidy — ex-45X, FY25 gross profit would be a ~$(105)M loss. Q1 2026 showed real operational improvement — 16.4% gross margin, a “record” $9.1M adjusted EBITDA — but GAAP EBITDA was only ~$2.6M, the $(20.4)M net loss was flattered by ~$30M of non-cash warrant/derivative gains, ~$52M of the quarter’s revenue was purchase-accounting deferred-revenue unwind, interest coverage is below 1x, and the balance sheet carries ~$550M of debt against ~$46M of cash, negative tangible common equity, and a $1.1B accumulated deficit.

The investment question is not “is this a good business” — it plainly is not. Solar-module assembly is a commodity in deep global oversupply (China >80% of supply, ASPs ~$0.10–0.30/W, 30–40GW of US module oversupply). T1 buys its cells, licenses its cell technology, and operates a single sub-scale plant. It has no supply-cost advantage, no customer captivity, and no scale-plus-captivity — no Greenwald moat of any kind. Its entire economics come from one policy line: the Section 45X Advanced Manufacturing Production Credit (~$0.07/W on modules), which at G1’s run-rate is worth ~$217–294M/year — larger than the company’s entire gross profit. Strip 45X and T1 loses money on every module.

That is exactly what a three-firm short campaign says is happening. Culper Research (Jan 2026) branded T1 “operationally and economically subject to China-based Trina Solar.” Fuzzy Panda (May 19 and June 10, 2026) alleges — via a whistleblower’s 26 invoices — that T1 bought >$65M of Trina (Chinese) solar cells in Q1 2026, the same quarter executives publicly claimed a switch to non-Chinese, FEOC-compliant suppliers; that its Material Assistance Cost Ratio is ~19% against a required 50%; and that the $41.4M of Q1 2026 45X credits must be reversed, turning the “$9.1M record adjusted EBITDA” into a −$32.3M loss. T1 has issued no formal rebuttal. Surrounding this are a DOJ grand-jury subpoena and SEC document request (a director’s 2H-2023 stock sales), the CAO’s termination two weeks after the first short report, terminated-and-litigated customer offtake (RWE), securities class actions, and a going-concern-caveated balance sheet funded by serial distressed dilution.

Against that sits real optionality. The Section 232 polysilicon tariff decision is expected within days (~July 4, 2026); because T1 uses American polysilicon (Hemlock), hard per-watt tariffs would raise rivals’ costs while sparing T1 — a legitimate “one-way” upside — and could force a violent short squeeze in a heavily-shorted ~$2.5B float. The result is a bimodal, event-driven security: plausibly worth low-double-digits if §232 lands and FEOC compliance holds; plausibly near-zero if the auditor forces a restatement or the federal matters escalate. This article takes no position; it maps the expectations embedded at ~$8.50–9.50 and the evidence that would resolve each side.

2. Business Overview

What T1 does. T1 Energy manufactures and sells crystalline-silicon photovoltaic (PV) solar modules for the US utility-scale, commercial, and (nascent) residential markets. Essentially all revenue comes from one asset: G1_Dallas, a 5-gigawatt-nameplate module-assembly plant in Wilmer, Texas, acquired from China’s Trina Solar in December 2024 and reportedly one of the largest and most modern module lines in the Western hemisphere. The company assembles modules from purchased solar cells, glass, aluminum frames, encapsulant, junction boxes, and backsheet; it does not yet manufacture its own cells (the input that represents roughly half the bill of materials). The forward strategy is to close that gap by building G2_Austin (in Rockdale, TX) — a 2.1GW-Phase-1 TOPCon solar-cell fab, with first cell production targeted for Q4 2026 and a potential Phase 2 taking capacity above 5GW.

How it makes money. T1 sells modules under a mix of (i) cost-plus / fixed-margin offtake contracts (~3GW contracted for 2026, the source of Q1’26’s improved margin) and (ii) merchant/spot sales at prevailing (depressed) market prices. Layered on top — and economically decisive — is the Section 45X production tax credit the company earns for US-made modules (a per-watt federal subsidy, refundable/transferable), plus the price premium its US-made, high-domestic-content product can command because it lets developers claim the Section 48E +10% domestic-content ITC bonus and remain FEOC-compliant. Revenue is thus a blend of module price + subsidy capture; the subsidy is the profit.

Segments / end markets. Effectively a single reportable operation (US PV modules). The intended end market is utility-scale solar developers whose demand, management says, is driven by hyperscaler/AI datacenter power needs — but the actual customer base today is startlingly concentrated: a single customer accounted for ~100% of Q1 2026 net sales and 100% of trade receivables, and related-party (Trina) sales were 77.7% of FY2025 revenue. In other words, T1 currently sells almost its entire output back to the Chinese company it bought the plant from, largely under an offtake agreement established in the acquisition’s purchase accounting (from which $52.2M was recognized as revenue in Q1’26 alone, against ~$138M of deferred revenue still on the balance sheet). Legacy FREYR battery operations (Norway/Luxembourg) were wound down and are reported as discontinued (though a small June 2026 KORE Power BESS acquisition re-enters storage). Third-party developer demand is thin and unstable: the largest arms-length offtake, with RWE, was terminated and is in litigation.

Corporate facts. Incorporated in Delaware; headquartered in Austin, Texas; FY-end December 31. ~328 corporate employees plus ~1,200 at G1_Dallas. NYSE: TE (warrants trade as TE-WT). CEO/Chairman Dan Barcelo; CFO Joseph (Evan) Calio; COO Jaime Gualy; Chief Legal & Policy Officer Andy Munro (who runs the FEOC/policy strategy). The company is the renamed FREYR Battery, Inc. (rebranded February 2025). Fact: company profile, FY25 10-K, Q1’26 10-Q.

Recurring vs. non-recurring. There is essentially no recurring revenue — modules are one-time hardware sales into a cyclical, price-taking market; the “annuity” the bulls point to is the 45X credit stream, which recurs only as long as (a) the statute survives, (b) the company qualifies under FEOC, and © it keeps producing. All three are contested.

Verdict: A single-asset, capital-intensive commodity manufacturer in its first full operating year, whose product is undifferentiated and whose profitability is a government subsidy rather than a market outcome. Comprehensible business; poor economics without policy support.

3. Industry Dynamics

Structure: a globally-oversupplied commodity, fenced off in the US by policy. Solar-module manufacturing is one of the least attractive industries in the energy-transition value chain. China controls >80% of global module production and a similar or greater share of upstream polysilicon, wafers, and cells; years of subsidized capacity build have driven global module ASPs to ~$0.10–0.30/W, below the cash cost of most non-Chinese producers. First Solar’s CEO testified to the Senate that the US carries a 30–40GW module oversupply amid “relentless Chinese subsidization and dumping.” More than 21GW of US clean-power capacity has been cancelled since the start of 2025 (over 8GW in Q1 2026 alone), as tariff/policy whiplash and interconnection bottlenecks stall projects. This is a textbook Marathon “capital-cycle” danger zone: heavy, subsidy-driven capacity being added into structural oversupply — a setup for capital destruction unless the policy fences hold.

The US policy stack is the entire investment case — so it must be understood precisely (all Fact, sourced to statute/guidance):

• Section 45X (Advanced Manufacturing Production Credit): a per-unit federal credit for US-made solar supply-chain components — ~$0.07/W for modules, ~$0.04/W for cells, $12/m² wafers, $3/kg polysilicon; refundable/transferable. For T1 at ~3.1–4.2GW of module output, module-45X alone is worth ~$217–294M/year. OBBBA (enacted July 4, 2025) preserves full value through 2029, then phases it down (≈75%/50%/25% in 2030/31/32) to zero after 2032.
• FEOC / Material Assistance Cost Ratio (MACR), effective Jan 1, 2026: OBBBA + IRS interim guidance (Notice 2026-15, Feb 2026) condition 45X/45Y/48E on (a) not being a Prohibited Foreign Entity and (b) clearing a MACR = (total direct material cost − PFE-sourced material cost) / total direct material cost. Solar 45X components must clear 50% in 2026, rising to 85% by 2030. Until Treasury issues safe-harbor MACR tables (due by 12/31/2026), taxpayers may rely on supplier certifications — the precise mechanism T1 leans on and the shorts attack.
• Section 48E (clean-electricity ITC — the developer’s credit): base 30% (with wage/apprenticeship), +10% domestic-content bonus, +10% energy-community. This adder is why US-made modules command a premium. OBBBA requires projects to begin construction within 12 months of enactment (~July 4, 2026) or be placed in service by end-2027 — creating a 1H-2026 demand pull-forward and a post-July demand cliff management repeatedly flagged.
• Section 232 polysilicon investigation: Commerce opened a national-security probe (July 1, 2025) into imported polysilicon and derivatives (wafers/cells/modules); the report was due to the President ~March 28, 2026, with a decision window into mid-2026 — widely expected around July 4, 2026. Proposed remedies floated include $0.20/W on modules, $0.10/W on cells, $0.07/W on wafers, $10/kg on poly. Because T1 buys domestic poly (Hemlock) and wafers (Corning/Nextpower), tariffs would raise rivals’ input costs while sparing T1 — management’s “favorable one-way option.” A separate IEEPA tariff refund is a further potential (litigation-dependent) upside on cells T1 imported.

Barriers to entry / switching costs. In the physical business, essentially none: module assembly is low-differentiation, cell technology (TOPCon) is licensable, and modules are interchangeable commodities with negligible switching costs. The only real barrier is the regulatory wall — AD/CVD duties, UFLPA import bans, potential §232 tariffs, and 45X/48E subsidies — which collectively keep Chinese product out and let compliant US-made product earn a policy premium. That wall is real but politically revocable and legally contested.

Verdict: structurally bad industry, temporarily made viable for US producers by a subsidy-and-tariff regime that is itself the biggest risk factor. A good business does not need a statute to be profitable; this one does.

4. Competitive Position

The competitive set. US module/cell competitors include First Solar (FSLR) — vertically integrated, proprietary CdTe thin-film, a genuine cost and IP moat and the clear quality leader; Qcells/Hanwha — building a fully integrated ingot-to-module complex in Cartersville, GA; Canadian Solar (CSIQ), JinkoSolar (JKS), Maxeon (MAXN), Silfab, Heliene, ES Foundry, and cell startup Talon PV (in which T1 holds a small SAFE stake). Against these, T1 is a single-plant, sub-scale module assembler that does not yet make its own cells.

Apply the Greenwald test rigorously — and T1 fails all three genuine advantage types:

• Supply / cost advantage: none. T1 purchases cells, polysilicon, wafers, glass, and frames; its cell technology is licensed (from Trina, via the Evervolt entity), not owned; its 5GW is trivial against China’s multi-hundred-GW scale. It is a price-taker on inputs and outputs alike.
• Demand / customer captivity: none — and worse, the demand is circular. Modules are fungible; there is no installed base, no ecosystem lock-in, no switching cost. The arms-length evidence is negative: T1’s largest third-party offtake, RWE, terminated its contract and is in litigation. What remains is not captivity but circularity: ~100% of current sales go to Trina — the related party that sold T1 the plant, seller-financed the deal, licensed it the cell technology (via Evervolt), collects a 5%-of-EBITDA “Sales Agency” fee in COGS, and is now selling down its stock (22.5M shares dumped in May 2026). That is the opposite of a durable customer franchise; it is a related-party structure whose central counterparty is heading for the exit.
• Economies of scale + captivity: none. No scale (sub-scale plant), no captive demand — the combination Greenwald requires for a durable franchise is simply absent.

So what is the “moat”? A subsidy plus a tariff wall — 45X per-watt credits and the domestic-content premium, protected by AD/CVD/UFLPA/§232 barriers. That is not a competitive advantage in any Greenwald sense; it is a contingent government transfer that (i) accrues to every compliant US producer, not T1 uniquely, (ii) can be legislated or regulated away, and (iii) — per the short thesis — may not even be validly captured by T1 given its dependence on Chinese IP and (allegedly) Chinese cells. A moat, properly defined, is an advantage whose removal would deteriorate a financial outcome the company earned. Here, removal of the subsidy deteriorates the financials to losses, and the subsidy was never earned competitively — so it is not a moat. Say it plainly: T1 has no durable competitive advantage.

Relative to First Solar — the correct benchmark for “what a real US-solar moat looks like” — the contrast is stark: FSLR owns its differentiated technology, is fully integrated, runs structural gross margins many multiples of T1’s ~7–17%, generates real free cash flow, and does not depend on Chinese inputs. T1 is the un-moated, policy-levered, governance-impaired opposite.

Verdict: crowded, commoditized market; weak-to-nonexistent differentiation; the only “advantage” is a revocable subsidy that may be improperly claimed.

5. Growth History and Forward Opportunities

History. As FREYR, the company was pre-revenue and cash-consumptive through 2021–2024 (annual net losses of $93M/$99M/$72M/$450M), with the 2024 loss dominated by the wind-down of the battery business (discontinued operations). Revenue is therefore a 2025 phenomenon and reflects the Trina/G1 acquisition, not organic build: FY2024 revenue was $2.9M (an empty shell); FY2025 revenue was $755.3M as G1_Dallas ramped to nameplate through the year (management says it hit capacity in Q4 2025). This is acquired, ramp-driven growth off a zero base — not a demonstrated growth engine.

Forward opportunities (all real, all contingent):

• G1 utilization & mix: 2026 production guidance of 3.1–4.2GW (vs a ~2.7GW Q1’26 run-rate), with margin driven by the ~3GW of cost-plus/fixed-margin contracts plus merchant upside. The bull case is a “meaningfully busier” 2H 2026 after the July safe-harbor deadline.
• G2_Austin cell fab: the genuine step-change — making its own TOPCon cells would let T1 produce high-domestic-content modules (stacking module-and-cell 45X, and enabling customers’ 48E adder). First cell targeted Q4 2026; but ~$225M of Phase-1 capex is still unfunded and one short report alleges the site is far behind schedule.
• Section 232 upside: poly tariffs would widen T1’s domestic-poly advantage in 2026 and (management says) more materially in 2027 as G2 ramps.
• Non-binding ambitions: a ~$5B Saudi (Manaar Gulf) Heads-of-Agreement for G2 expansion (still non-binding/unfunded) and a Nextracker supply/offtake partnership.

Quality of growth: low. It is acquired, subsidy-dependent, single-customer-fragile (RWE gone), and gated by financing the company does not yet have. The demand narrative (hyperscaler/AI power) is credible at the industry level but does not confer pricing power on an un-moated assembler; indeed 2026’s demand is partly a pull-forward ahead of a policy cliff, not durable secular growth for T1 specifically.

Verdict: low-quality, acquired, policy-gated growth off a zero base — not the high-quality organic compounding the multiple would need to justify.

6. Financial Quality

Income statement. FY2025: revenue $755.3M, gross profit $55.6M (7.4% margin), operating loss −$179.7M, net loss −$367.8M, diluted EPS −$2.19; EBITDA −$86.4M. The reported line items are muddied by ~$161M of non-operating income (warrant/derivative and other items) and a $77M asset impairment. Gross margin of 7.4% is razor-thin even before noting that the 45X credit — recognized as a reduction of cost of goods sold — is what makes gross profit positive at all. Q1 2026 improved to a 17% gross margin and a “record” $9.1M adjusted EBITDA on 683MW of throughput — but GAAP EBITDA was only ~$2.6M, GAAP operating income was −$22.5M, and interest expense (~$6.2M/quarter) is not covered by EBITDA (EBITDA/interest ≈ 0.4x).

The 45X dependency is the whole story — and now quantified. T1 books 45X as a contra-cost-of-sales government grant. In December 2025 it agreed to sell ~$160M of its 2025-vintage 45X credits for $145.6M (a ~9% haircut) — so the credit is the gross profit: against FY25 gross profit of $55.6M, stripping the ~$160M of 45X credits implies an ex-subsidy gross loss of roughly $(105)M. The same holds in Q1’26 — the grants-receivable roll-forward rose $41.4M in the quarter, and gross profit of $29.1M is smaller than the credits generated, so the module business runs at a gross loss ex-45X in both periods. Fuzzy Panda’s central claim is therefore arithmetic, not rhetorical — reverse the $41.4M of Q1’26 45X credits and the “$9.1M record adjusted EBITDA” becomes −$32.3M. Whether or not the short is right about why, the sensitivity is undisputed: the “E” in any earnings story is a government transfer, monetized at a discount.

Revenue quality is further flattered by non-cash and acquisition accounting. Of Q1’26’s $177.6M revenue, $52.2M was recognized from the Trina purchase-accounting deferred-revenue liability (a non-cash unwind, not fresh commercial demand), and the reported $(20.4)M net loss was helped by ~$30M of non-cash warrant ($10.4M) and derivative ($20.0M) fair-value gains — without which the pre-tax result would have been materially worse.

Cash flow — the reported FCF is an illusion. FY2025 shows +$95.5M operating cash flow and ~$16.7M “free cash flow” — but this is a working-capital artifact: inventories were drawn down by +$158.5M and payables rose +$135M, together contributing ~$294M of working-capital release that masks an operating business still burning cash. (Note ROIC’s headline “$756M TTM free cash flow” figure is spurious and should be ignored.) The tell is the cash balance: it swings from $8.5M (Q2’25) to $34M (Q3) to $182M (Q4, post-raise) to $46M (Q1’26) — a company living hand-to-mouth on episodic capital raises, not internal generation. FY2024 free cash flow was −$154M; FY2023 −$276M.

Balance sheet — fragile, over-levered, negative tangible equity. At Q1 2026: cash $46.4M (plus $70.2M restricted); total debt $549.8M (short-term borrowings $65.5M + long-term $484.2M, including ~$154M of capital leases); net debt $332M; preferred $72.5M (Encompass, a related party). Total equity is $309M, but it contains $226.6M of intangibles and $57.4M of goodwill from the Trina deal — so tangible common equity is roughly zero and negative net of preferred. Accumulated deficit −$1.11B. Leverage is extreme: total-debt/equity ~178%, and EBITDA does not cover interest. Scheduled long-term debt maturities total $418M (2026 $46M / 2027 $52M / 2028 $72M / 2029 $87M / 2030 $161M), on top of which sit two convertible issues — $161M of 5.25% notes due 2030 (Dec 2025) and $184M of 4.00% notes due 2031 (April 2026, conversion ~$6.80). Management asserts no going-concern doubt (cash “sufficient…for at least the next 12 months”), but the 10-K also warns that if indebtedness were accelerated, “there can be no assurance that our assets would be sufficient to repay this indebtedness in full, which could have a material adverse effect on our ability to continue to operate as a going concern.” With ~$46M of unrestricted cash against ~$73M of quarterly operating burn, this is a balance sheet living on episodic capital-markets access.

Dilution — relentless, and about to accelerate. Shares outstanding: ~75M (2021) → 156M (2024) → 169M (Q3’25) → 266M (Q4’25) → 279M (Q1’26) — roughly a 3.7x increase, much of it struck at distressed prices ($1.70–$1.90 Encompass preferred; equity issued in the low single digits). Add the ~$345M of convertibles (conversion ~$6.80 on the larger issue) and — the loudest signal — a June 2026 shareholder vote to raise authorized shares from 500M to 1 billion. (The legacy TE-WT public warrants, 14.8M at an $11.50 strike, are out-of-the-money and expire July 9, 2026 — a rare reduction in overhang.) Per-share value has been continuously transferred from existing holders to financiers, and the doubled authorization signals management expects to keep doing so.

ROIC/ROE. Meaningless in the conventional sense — returns on capital are deeply negative (ROA −27% FY25), and the equity base is largely intangible. There is no evidence that economics improve with scale; the improvement in Q1’26 came from contract mix and 45X capture, not structural unit economics.

Verdict: poor financial quality. Thin, subsidy-dependent margins; illusory reported FCF; a leveraged, negative-tangible-equity balance sheet reliant on continuous dilution; and a going-concern-caveated liquidity position. Economics do not visibly improve with scale absent the subsidy.

7. Capital Allocation

The record is survival-financing, not value-accretive deployment.

• The Trina acquisition (Dec 2024, $406.8M) — buying the 5GW G1 plant — was heavily seller-financed (cash $150.6M + $39.5M equity + ~$198M of Trina notes + an $18.5M anti-dilution right), leaving the “American manufacturing” pivot funded by, IP-licensed from, ~100%-sold-back-to, and 5%-of-EBITDA-agency-fee-paying to the Chinese seller. That tether is precisely what triggers the FEOC/PFE risk and the short campaign.
• The FEOC restructuring (Dec 2025) — discharging the $150M Trina AG note via a payoff letter, removing Trina’s board-nomination rights, capping Trina equity below the 25% OBBBA limit, and moving the cell-technology license to Evervolt (Singapore) — was an attempt to engineer 45X eligibility. Whether it works is the binary at the heart of the thesis; the shorts call Evervolt a Trina/CETC front and the license a post-cutoff “workaround.”
• Trina is now exiting. In May 2026 Trina sold 22.5M shares on the open market (discretionary, ~$185–190M), cutting its stake from ~52.7M to ~30.7M shares (~11%) — the strategic “partner” whose offtake is the revenue base heading for the door within ~18 months of the deal, and a large remaining overhang.
• Financing stack (serial, dilutive, related-party): an Encompass (related party) preferred — $50M Series A (Dec 2024) plus Series B/B-1 (Oct 2025), $10 stated value; two converts ($161M 5.25% due 2030; $184M 4.00% due 2031); and continuous equity issuance. G2 still needs ~$225M management hopes to raise as debt “in 2Q 2026,” and shareholders doubled the authorized share count to 1 billion (June 2026).
• Diversification/optionality: a ~$5B Manaar Gulf (Saudi) Heads-of-Agreement for G2 (still non-binding/unfunded), a Nextracker partnership, a $5M SAFE into Talon PV (alternative cell source), and a small June 2026 KORE Power BESS acquisition (~$32M EV, ~$9.6M in stock + earnout) re-entering storage — a curious re-diversification for a company that just exited batteries and cannot fund its core cell fab.

Incentives & governance — multiple red flags. The CAO (Denise Cruz) was terminated February 5, 2026, two weeks after Culper’s report (replaced by Tom Mahrer). The company and a director received DOJ grand-jury subpoenas (Nov 2025) and an SEC document request over 2H-2023 stock sales. Culper alleges the CEO scrubbed prior Russian-firm roles from his bio. A wave of Form 144 proposed-sale filings by insiders in May–June 2026 — into the post-earnings pop — is the opposite of the open-market buying that would signal conviction. There is no evidence of shareholder-friendly capital return (no buyback, no dividend, and none would be appropriate for a cash-burner); the question is purely whether management is preserving or destroying per-share value, and the dilution record answers it.

Verdict: weak capital allocation and elevated governance risk. A serially-diluting former failed SPAC bought a Chinese-financed plant it remains dependent on, funds itself with distressed paper, dangles unfunded mega-deals, and is now under federal investigation with a fired CAO. This is not a management team to underwrite on trust — and management commentary here must be treated as hypothesis, not evidence, more than usual.

8. Changes and Headwinds — Last Two Years

The last 24 months are the story — this is a company that changed its identity, industry, and capital structure:

• Identity/industry pivot: wound down the FREYR battery business (Norway/Luxembourg), acquired Trina’s US module plant (Dec 2024), rebranded to T1 (Feb 2025).
• Regulatory regime shift: OBBBA (July 2025) preserved but began phasing 45X and layered on the FEOC/PFE rules (effective Jan 1, 2026) that now threaten eligibility; Section 232 poly investigation launched (July 2025), decision imminent.
• The short siege: Culper (Jan 21, 2026); Fuzzy Panda #1 (May 19) attacking the Evervolt IP structure; Fuzzy Panda #2 (June 10) with whistleblower invoices alleging >$65M of Q1’26 Chinese cell purchases and a required 45X reversal. No formal company rebuttal.
• Governance/legal: DOJ grand-jury subpoena + SEC request (director’s 2H-2023 stock sales); CAO terminated (Feb 2026); RWE offtake terminated and in litigation; multiple securities class actions filed.
• Capital structure: share count roughly doubled again (Q3→Q4 2025); two converts ($161M Dec 2025 + $184M April 2026); Encompass preferred; authorized shares raised 500M→1B (June 2026); ~$225M G2 funding gap outstanding; Trina’s 22.5M-share May-2026 sell-down.
• Related-party partner exit: Trina relinquished its board seats (Dec 2025) and sold ~43% of its stake (May 2026) — even as it remains ~100% of T1’s current customer base.
• Small offsetting items: a ~$32M KORE Power BESS acquisition (June 2026); a $33.5M IEEPA tariff-refund claim filed after the Supreme Court invalidated the IEEPA tariffs (Feb 2026), not yet booked (potential upside).
• Operational positives (to be fair): G1 reached nameplate; Q1’26 gross margin and adjusted EBITDA genuinely improved on contract mix; G2 construction reportedly on schedule for Q4’26 first cells; Nextracker and domestic-supply (Hemlock/Corning) relationships advanced.

Verdict: on balance these developments weaken the thesis. The operational ramp is real and welcome, but it is overwhelmed by the compounding of policy, accounting-integrity, governance, and financing risks. The single most important change — FEOC rules going live while the company is (allegedly) sourcing Chinese cells — strikes directly at the only source of profit.

9. Risk Analysis (Risk Matrix)

The risks are unusually correlated: a FEOC/45X failure would simultaneously erase profitability, likely trigger a restatement, aggravate the DOJ/SEC matter, and choke financing — the tail scenarios reinforce one another. That correlation is why the equity is best understood as a binary rather than a distribution with a fat but survivable left tail.

10. Valuation Discussion (Embedded Expectations)

No price target, no recommendation — the goal is to characterize what ~$8.50–9.50 embeds. At ~279M shares (pre-full-dilution) and ~$8.56, market cap is ~$2.4B; add ~$0.33B net debt and ~$0.07B preferred for an enterprise value of ~$2.8B (ROIC’s clean EV run ~$1.8–2.9B across recent quarters). Conventional multiples are unusable or misleading: no P/E (losses); P/B ~4.6x (82nd percentile of its own short history — “rich” on a book that is mostly intangible); P/S ~2.5x (26th percentile); EV/Sales ~2–3.5x; EV/EBITDA negative. Tangible book is ~zero, so P/TBV is meaningless. The valuation-percentile signal is low-quality here (thin history, distorted GAAP), so read it only as: not cheap on assets, not obviously expensive on sales — because sales are a gross-up of a subsidy-dependent commodity.

The right frame is a scenario/option model on the 45X binary, not a DCF:

• Bear (FEOC fails / restatement, ~30–40% weight): the $41.4M/quarter 45X capture is disallowed or reversed; adjusted EBITDA is structurally negative; a restatement and the DOJ/SEC matter impair financing; the going-concern caveat bites. In this world the equity is worth a small fraction of today’s price, plausibly approaching zero after debt and preferred. There is no asset floor — a commodity module line in oversupply has low liquidation value and the balance sheet has negative tangible equity.

• Base (FEOC holds, no §232 windfall, ~40–50% weight): G1 runs 3.1–4.2GW at mid-teens gross margin with 45X, G2 comes on in 2027, and T1 reaches a mid-cycle ~$150–250M EBITDA run-rate once both plants operate. On 6–8x EV/EBITDA (generous for a no-moat, policy-levered, governance-impaired commodity manufacturer) that is ~$1.0–2.0B EV; net of ~$0.4B net debt+preferred and spread over a diluting ~300M+ share count, the business is worth roughly $4–7/share — below today’s price. The market is already paying for some of the upside case.

• Bull (FEOC holds and §232 lands hard, ~15–25% weight): per-watt poly/cell/module tariffs widen T1’s domestic-poly advantage, ASPs and margins step up, G2 stacks cell-45X, the demand cliff proves shallow, and a heavily-shorted float squeezes. Here you can sketch low-double-digits to high-teens — a genuine multi-bagger from the 2024 low, and the reason the stock has already 9x’d.

Scenario summary (illustrative, not a target — assumptions explicit):

The distribution is deliberately bimodal — a probability-weighted “expected value” in the mid-single-digits is almost meaningless because the outcome is unlikely to land there; it resolves toward one tail or the other on the FEOC/232 catalysts. This is an option payoff, not a normal distribution, which is exactly why a fundamental fund cannot size it as a core position.

Embedded-expectations read: at ~$8.50–9.50, the market is pricing something close to the base-to-bull blend — i.e., it is underwriting that FEOC compliance holds and that §232/optionality is worth real money, while assigning modest weight to the restatement/zero tail. Given (a) three short sellers plus a whistleblower plus the DOJ all attacking exactly the FEOC assumption, and (b) no company rebuttal, that looks like the market is under-pricing the left tail. The stock is not “cheap”; it is a fairly-to-richly-priced call option on a contested subsidy, where the strike is “the accounting is clean.”

11. Variant Perception

Consensus view (as reflected in the tape and the lone sell-side note): T1 is a turnaround — a distressed former SPAC that bought a world-class US module plant at the bottom, is executing an operational ramp (Q1’26 proved it), sits at the “nexus of US energy policy” with 45X + domestic-content premiums + a §232 call option, and will re-rate as G2 de-risks and tariffs land. Bernstein’s Market-Perform/$9 and Roth’s “buy the dip / misleading short report” capture the constructive-but-cautious middle.

Strongest bull case: US solar demand is structurally short (AI/hyperscaler power), domestic FEOC-clean supply is genuinely scarce, T1’s American-poly sourcing is a real §232 hedge, and if the compliance questions are resolved cleanly the equity is dramatically undervalued versus a $150–250M+ EBITDA future. The short reports, on this view, are talking their book and the invoices are explained by the licensed-IP/Evervolt restructuring.

Strongest bear case: the profits are a mirage. T1 is an un-moated commodity assembler whose only earnings are a subsidy it may be improperly claiming on Chinese cells; the numbers require a restatement; the DOJ/SEC are already involved; the CAO is gone; the customer (RWE) sued; the balance sheet is a going-concern with negative tangible equity funded by serial dilution; and the “growth” (G2) is unfunded. Strip the subsidy and there is no business — only losses and debt.

The 3–5 assumptions that actually matter:

1. Does T1’s sourcing clear the FEOC/MACR 50% threshold? (The whole equity turns on this.)
2. Will the auditor/DOJ/SEC force a 45X restatement?
3. Does §232 land with hard per-watt tariffs, and soon?
4. Can T1 fund G2’s ~$225M gap and stay liquid without ruinous dilution?
5. Is post-July-2026 demand a cliff or a plateau?

Falsification tests. Bull is falsified if T1 restates 45X, the MACR is confirmed below 50%, or the DOJ/SEC matter escalates. Bear is falsified if T1 publishes credible, independently-verifiable FEOC compliance documentation (supplier-of-record chain), §232 lands favorably, and G2 is fully funded on non-dilutive terms.

Factor-positioning input (not a price call). The tape confirms the “speculative option” framing: beta ~1.7, R² ~21–25% (mostly idiosyncratic), a −94% five-year max drawdown, and a ~+100% raw move last quarter — a violently volatile microcap. Crucially, FactorsToday’s factor-similar peers are EVGO, ASTS, LEU, SLI — pre-profit clean-energy/space “story” stocks, not solar manufacturers. The market is not pricing T1 as an industrial; it is pricing it as a thematic lottery ticket. That is consistent with consensus being offsides in both directions at once — over-loving the theme, under-weighting the fraud tail.

12. Fact vs. Interpretation

13. Open Questions

1. Will Treasury’s forthcoming safe-harbor MACR tables and PFE-status guidance validate or void the Evervolt/supplier-certification structure? Binary and currently unknowable.
2. Has the auditor signed off on the Q1’26 45X treatment, and is a restatement of Q1’26 (or FY25) in prospect? No formal company response to the invoice allegations exists as of the report date.
3. What is the exact fully-diluted share count including all preferred conversion, the $160M convert (~$6.80), and TE-WT warrants? The overhang is large and cheaply struck.
4. Will §232 land, when, and in what form (per-watt tariff vs TRQ), and does a cell tariff help (rivals’ modules) or hurt (T1’s own imported-cell inputs) T1 in 2026 specifically?
5. Can G2’s ~$225M gap be funded on non-dilutive terms in 2H 2026, and is the site actually on schedule for Q4’26 first cells (company) or 12–18 months behind (short)?
6. What is the real, sustained, ex-subsidy unit economic of a G1 module — i.e., the gross margin with the 45X credit stripped out — quarter by quarter?
7. How large and discretionary is the May–June 2026 insider selling (Form 144 wave), and is any of it 10b5-1-planned vs. conviction-signaling discretionary?

14. What Must Be True

For the bull case to be right (and its falsification test):

• T1’s cell sourcing genuinely clears the FEOC/MACR 50% threshold and the 45X credits are validly earned and durable. Falsified if the MACR is confirmed <50%, T1 restates 45X, or the DOJ/SEC matter produces charges.
• §232 lands with hard per-watt tariffs, widening T1’s domestic-poly advantage, and post-July demand does not fall off a cliff. Falsified if §232 is toothless/delayed or 2H-2026 orders collapse.
• G2 is funded on non-dilutive terms and reaches Q4’26 first cells roughly on schedule, delivering the cell-45X + domestic-content step-change. Falsified if the $225M gap forces more distressed equity or the site slips >12 months.

For the bear case to be right (and its falsification test):

• The 45X profit is improperly claimed on Chinese cells; a restatement flips “profits” to losses and the subsidy is the only thing standing between T1 and cash-burn insolvency. Falsified if T1 publishes independently-verifiable supplier-of-record documentation proving FEOC compliance and the auditor/regulators clear the treatment.
• The un-moated commodity core cannot self-fund; continued dilution and a going-concern balance sheet erode per-share value regardless of the policy outcome. Falsified if T1 reaches sustained positive ex-subsidy unit economics and self-funds G2.

The single cleanest test that resolves the most: an independent, audited confirmation of T1’s Q1’26 Material Assistance Cost Ratio and cell supplier-of-record — clearing >50% kills the bear’s core; confirming <50% (or a restatement) kills the bull’s core. Everything else is secondary to that one number.

15. Source Appendix

Primary and quantitative sources are consolidated in Appendix B — Source Appendix below. Core primary sources: T1 Energy FY2025 Form 10-K (t1-20251231), Q1 2026 Form 10-Q (t1-20260331), 2024–2026 Forms 8-K (including the Feb 2026 CAO-change and April 2026 convertible-notes filings), DEF 14A proxy, and Forms 3/4/144; the Q1 2026 earnings-call transcript (ROIC.ai, May 12 2026); ROIC.ai fundamentals/ratios/EV; AZI price history and news feed; FactorsToday factor model; IRA §45X / OBBBA statute and IRS Notice 2026-15; Commerce §232 polysilicon docket; and the Culper Research (Jan 2026) and Fuzzy Panda Research (May 19 / June 10 2026) short reports with cited media coverage.

APPENDIX A — Standard Diligence Questionnaire — T1 Energy Inc. (NYSE: TE)

Supplemental to the research memo. Report date 2026-07-03. Fact / Interpretation / Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company? The dominant investor debate is binary and singular: does T1 actually qualify for the Section 45X tax credits that are its entire profit? Sub-questions: Is the Evervolt IP structure a legitimate FEOC workaround or a Trina/CETC front (Interpretation, contested)? Will the Q1’26 $9.1M “adjusted EBITDA” survive audit, or be restated to −$32.3M as Fuzzy Panda argues (Open Question)? Can T1 fund G2’s ~$225M gap without ruinous dilution (Open Question)? Will Section 232 poly tariffs land and squeeze the heavily-shorted float (Open Question)? And structurally: how can revenue be ~100% related-party (Trina) and the demand story be “hyperscaler-driven”? Bulls (Roth) frame the shorts as book-talking; skeptics (Culper, Fuzzy Panda) frame the whole entity as a China-tethered subsidy-harvesting shell.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? There are no earnings — T1 is loss-making (FY25 net loss −$367.8M; Q1’26 −$20.4M). “Adjusted EBITDA” turned marginally positive in Q1’26 ($9.1M) purely on 45X capture and a favorable contract mix. Interpretation: margins are at an artificial, policy-supported level, not a cyclical high or low in the normal sense — they are entirely a function of subsidy eligibility and a 1H-2026 demand pull-forward ahead of the July 48E safe-harbor deadline.

Driven by external environment or internal actions? Overwhelmingly external: 45X/48E statute, FEOC rules, tariff policy (232/IEEPA/AD-CVD), and Chinese module oversupply. Internal actions (ramping G1, building G2, contract mix) matter at the margin but cannot overcome negative ex-subsidy unit economics.

How stable are revenues? Unstable and low-quality — ~100% concentrated in a single related party (Trina), ~$52M/quarter of it a non-cash purchase-accounting deferred-revenue unwind, with the largest arms-length customer (RWE) terminated and litigating.

Outlook for products/services; how big is the market? US solar demand is genuinely large and growing (AI/datacenter-driven), but module manufacturing is a globally oversupplied commodity (China >80% share, ASPs $0.10–0.30/W, 30–40GW US oversupply). The addressable subsidy market is large but time-limited (45X phases down 2030–2032) and eligibility-gated.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More. US capacity is being added (Qcells integration, First Solar expansion, new cell fabs) into structural oversupply — a Marathon late-cycle capital-destruction setup, distorted only by policy fences.

How profitable is the business (ROIC, ROE)? Deeply negative. FY25 ROA −27%; ROE not meaningful (negative/mostly-intangible equity); ROIC negative. Ex-45X the business is gross-margin-negative.

How profitable is the industry; barriers to entry? Chronically unprofitable ex-subsidy for non-Chinese assemblers; low barriers (module assembly is commoditized, cell tech licensable). The only barrier is the tariff/subsidy regime.

Can the business be easily understood? Yes — that is not the problem. It is a single-plant module assembler monetizing a per-watt tax credit.

Can it be undermined by foreign low-cost labor? It already is — Chinese modules are structurally cheaper; T1 exists only because tariffs/subsidies offset that gap.

Do brands matter? Nature of competition? Switching costs? Brands are largely irrelevant in utility-scale modules; competition is on price, domestic-content eligibility, and bankability; switching costs are negligible. Verdict: no moat (see the Competitive Position section).

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? A $33.5M IEEPA tariff-refund claim (filed, not booked) is potential unrecognized upside. Otherwise the balance sheet is intangible-heavy, not conservative.

Off-balance-sheet liabilities? Operating leases are capitalized (ROU $151M). The larger “hidden” exposures are contingent: the 45X reversal risk, RWE litigation, securities class actions, and the DOJ/SEC matter — none provisioned.

How conservative is the accounting? Interpretation: aggressive-leaning on the items that matter — 45X recognized as contra-COGS on supplier certifications; deferred-revenue and non-cash derivative gains flattering the P&L; a fired CAO and short-seller restatement allegations. This is a low-trust accounting situation.

How CapEx-hungry? Very. FY23 capex −$188M, FY25 −$79M, and G2 requires ~$425M total (~$225M still unfunded). This is a capital-devouring build in an oversupplied industry.

Capital Allocation & Management

How much FCF; how is it used; philosophy? No genuine FCF — FY25’s reported +$16.7M “FCF” is a working-capital (inventory/AP) artifact; the operating business burns ~$73M/quarter. Capital allocation is survival-financing (serial converts/preferred/equity), not return-oriented.

Significant acquisitions? Trina US module plant (Dec 2024, $406.8M, seller-financed) and a small KORE Power BESS deal (June 2026). The Trina deal is the company; it also is the central risk.

Buying back shares? No — the opposite: relentless issuance (75M→279M shares) plus a June-2026 authorization increase to 1 billion.

Issuing large amounts of stock to insiders? Yes — large FY26 RSU grants (CEO 1.0M, CFO ~0.97M shares). No insider open-market purchases. The only large discretionary insider sale is Trina’s 22.5M-share disposal.

Compensation policy / motivations? Open Question on incentive metrics (proxy). Interpretation: the pattern — grants + dilution + a subpoenaed director’s 2H-2023 stock sales + a fired CAO + no insider buying — is a governance caution flag, not an alignment signal.

Valuation & Market Data

ADR / MLP / K-1? No — a Delaware C-corp, NYSE-listed common (TE); warrants TE-WT (expiring OOM July 9, 2026). Not a pass-through.

Dividend policy? None, and none appropriate for a cash-burner.

How profitable is the business? Unprofitable (see above).

Net income vs. cash from operations diverging? Yes — FY25 net loss −$368M vs reported OCF +$95M, the gap driven by non-cash items and a large working-capital release (inventory sell-through). The divergence flatters, rather than reassures.

Risks & Downside

What would cause the stock to decline? A 45X restatement / FEOC disqualification; DOJ/SEC escalation; a failed G2 financing or covenant breach; further Trina selling; an unfavorable or delayed §232; a post-July demand cliff; continued dilution. (See risk matrix, the Risk Analysis section.)

Risk of catastrophic loss / total loss? Interpretation: real and non-trivial. The combination of negative tangible equity, ~$550M debt, thin liquidity, and a scenario in which the subsidy (the only profit source) is disallowed produces a plausible path toward equity impairment approaching zero. This is why this analysis frames the security as bimodal.

Recent News & Events

Has the business environment changed recently? Dramatically — FEOC rules live (Jan 2026); OBBBA 45X phase-down + PFE restrictions; §232 poly decision imminent (~July 2026); a three-firm short campaign (Culper Jan; Fuzzy Panda May/June); DOJ subpoena + SEC request; CAO termination; Trina board-seat exit and stock sell-down; two convertible raises; authorized-share doubling; a small KORE Power acquisition; SCOTUS invalidation of IEEPA tariffs (refund claim pending). Interpretation: the net of these is a material increase in tail risk, only partly offset by genuine §232/IEEPA upside optionality and an improving G1 operating cadence.

APPENDIX B — Source Appendix — T1 Energy Inc. (NYSE: TE)

Report date 2026-07-03. Primary sources first. Third-party aggregated data is reconciled to filings where material.

Primary — SEC filings (T1 Energy / FREYR Battery, CIK 0001992243)

• Form 10-K, FY2025 (filed 2026-03-31; t1-20251231) — statements of operations; balance sheet; MD&A liquidity; Note 1 Government Grants (45X contra-COGS accounting); Note 7 Debt & Convertibles; Trina Business Combination note ($406.8M); Preferred Stock note; Business/Risk Factors (FEOC Restructuring, IEEPA tariffs); going-concern basis language.
• Form 10-K/A Amendment No. 1 (filed 2026-04-30) — Part III / technical amendment; shares out 279,071,590 as of 2026-04-28.
• Form 10-Q, Q1 2026 (filed 2026-05-12; t1-20260331) — Q1 income statement ($177.6M sales, 16.4% GM, −$20.4M net loss); balance sheet (cash $46.4M, debt $549.8M); Related-Party note (single customer ~100% of sales); Deferred-Revenue note ($52.2M recognized); Legal Proceedings (DOJ grand-jury subpoena + SEC request re 2H-2023 stock sales; RWE litigation); IEEPA $33.5M refund contingency; Material Assistance / FEOC disclosure.
• Prior 10-Ks / 10-Qs (FREYR 2023–2024; T1 2025 interims) — five-year history, discontinued battery operations, dilution trend.
• Forms 8-K (2024–2026) — Dec 2024 Trina acquisition; Feb 2025 rebrand; Feb 2026 CAO termination/appointment; April 2026 $184M 4.00% convertible notes; June 2026 KORE Power acquisition; June 2026 authorized-share increase (500M→1B); June 2026 warrant-expiry notice.
• DEF 14A proxy (filed 2026-05-18) — beneficial ownership (Trina 50.15M / 17.97% at record date); Cooperation Agreement (board-nomination rights removed Dec 2025); Sales Agency Agreement (5%-of-EBITDA fee to Trina); executive compensation.
• Forms 3/4/144 — Trina Solar (Schweiz) AG Form 4 (filed 2026-05-26): 22.5M-share open-market sale (Code S) May 21–22 2026, stake to ~30.65M; officer RSU grants (Code A) and tax-withholding (Code F) May–June 2026; departed CDO Kilde Form 144 proposed sales (~$3.65M). No Code P open-market purchases.

Primary — Company IR / calls

• Q1 2026 earnings-call transcript (2026-05-12; via ROIC.ai get_latest_earnings_call) — “record” $9.1M adjusted EBITDA, 17% gross margin, 683MW throughput; G2 first-cell target Q4 2026, ~$225M remaining capex; non-FEOC cell sourcing (4 vendors); §232 “favorable one-way option”; IEEPA refund; 3.1–4.2GW G1 2026 production guidance.
• T1 Energy Investor Relations (ir.t1energy.com) — “Update on T1 Energy FEOC Compliance Efforts”; FY2025 results release; transaction announcements (Trina, Manaar, Nextracker, Encompass).

Policy / statute / regulatory

• IRA §45X Advanced Manufacturing Production Credit (per-watt values); OBBBA (enacted 2025-07-04) 45X phase-down and FEOC/PFE restrictions.
• IRS Notice 2026-15 (Feb 2026) interim FEOC guidance; Material Assistance Cost Ratio thresholds (50% solar 2026 → 85% by 2030); supplier-certification reliance.
• §48E clean-electricity ITC (+10% domestic-content bonus); OBBBA begin-construction safe-harbor (~July 4, 2026).
• Section 232 polysilicon investigation (Commerce, launched 2025-07-01; report due ~2026-03-28; decision expected ~mid-2026) — proposed per-watt tariff structure; industry commentary (pv-tech.org, pv-magazine, Wood Mackenzie, ACORE/SEIA/ACP comments).
• IEEPA tariffs and Supreme Court invalidation (Feb 2026); T1 $33.5M refund claim.

Short-seller reports & media

• Culper Research (2026-01-21) — “operationally and economically subject to China-based Trina Solar”; RWE offtake, sales-vs-purchase discrepancies, CEO bio allegations.
• Fuzzy Panda Research — Part 1 “The Solar Cell Invoices” and “Short TE — Hidden Chinese Ties Will FEOC T1 Energy” (2026-05-19 and 2026-06-10); whistleblower 26 invoices, >$65M Q1’26 Trina cell purchases, MACR ~19% vs 50%, $41.4M 45X reversal → adj EBITDA −$32.3M; Evervolt-as-front claim.
• Benzinga, Stocktwits, Yahoo Finance, pv-magazine USA (“‘Buy the dip’… Roth”), TradingView, Fintool (CAO termination), ad-hoc-news — coverage of the reports, T1’s decline-to-comment, Bernstein initiation (Market Perform, $9), and the DOJ/SEC disclosures.

Market & quantitative data (third-party, reconciled to filings)

• Consolidated financial statements, profitability/credit/valuation ratios, enterprise value, per-share data, valuation multiples, and the Q1 2026 earnings-call transcript from third-party financial-data providers (reconciled to SEC filings).
• 5-year daily price/OHLCV history (5yr high $16.94 2022-10; low $0.91 2024-09; 52-wk $1.15–$12.49; ~$8.56 close 2026-07-02) and own-history valuation percentiles (P/B ~82nd, P/S ~26th, composite ~54th).
• Factor/risk analytics: Market beta ~1.66–1.72 (R² ~21–25%); 5-year annualized return −3%, max drawdown −94%; latest-quarter move ~+100% raw; factor-similar peers EVGO / ASTS / LEU / SLI (speculative thematic vehicles, not solar manufacturers).

Industry / competitive context

• Utility Dive, Canary Media, EnkiAI — US module oversupply (30–40GW), First Solar Senate testimony on Chinese dumping, 21GW+ US project cancellations.
• Competitor references: First Solar (FSLR), Qcells/Hanwha (Cartersville), Canadian Solar (CSIQ), JinkoSolar (JKS), Maxeon (MAXN), Silfab, Heliene, ES Foundry, Talon PV.